Apellis and Sobi report data from Phase II C3 glomerulopathy

Pegcetacoplan treatment resulted in sustained improvements in proteinuria and kidney function stabilisation.

Related Keywords

Caroline Baumal , Apellis Pharmaceuticals , Clinical Trials Arena ,